MYB NewsBusiness News
Markets
Business · 1 min read

Moderna reveals full Phase 3 data for its customized mRNA melanoma vaccine

Moderna shares a new melanoma vaccine trial.

Moderna reveals full Phase 3 data for its customized mRNA melanoma vaccine
Photo: Fletcher, CC BY 4.0, via Wikimedia Commons

The short version

  • The biotech company built an mRNA shot for tumors.
  • The study met goals with Merck and Keytruda.
  • Doctors will review the full data in Madrid.

Moderna, the biotech company known for its COVID-19 vaccine, is pushing into cancer treatment with a customized mRNA vaccine for melanoma. According to MarketWatch, researchers are presenting full Phase 3 data for the experimental therapeutic vaccine at a medical conference in Madrid after studies met primary and secondary endpoints alongside Merck, the pharmaceutical giant.

Janice Mehnert, a doctor at NYU Langone Health's Perlmutter Cancer Center, called the treatment a first-in-class approach. The vaccine, called intismeran, uses genetic data from a patient's removed tumor to create an individualized mRNA strand targeting mutated proteins. The six-week process pairs with Merck's Keytruda, an immunotherapy drug on track to bring in about $32 billion in sales this year.

Moderna's stock has soared 284% since the companies announced trial success in August, though investors and doctors await details on how long patients stay cancer-free. Daniel Olson, an oncologist at the UChicago Medicine hospital system, said the data will show if the treatment moves forward into clinics.

Analysts at Leerink Partners and William Blair are watching the hazard ratio for recurrence-free survival to gauge how much better the combination performs than Keytruda alone. A prior Phase 2b study showed a hazard ratio of 0.51 after about five years. The results could reshape how doctors treat skin cancer.

About Moderna

American biotechnology company

Share price
$195.00−2.17% last trading day
Market value
$9.5 billion2025
Revenue
$3.2 billiona year, 2024
Employees
5,8002024
Founded
2010
Based in
Cambridge
Chief executive
Stéphane Bancel
Owned by
ShareholdersNasdaq: MRNA

From Wikipedia and Yahoo Finance. Figures can be a year or two old.

Comment

More in business

See all

Comments

Talk business and keep it civil. A complaint about a private person or a local business goes to them first, not here.